Sonablate® HIFU

Indications and Approvals
Prostate Cancer
Benign Prostatic Hyperplasia
Prostate Cancer and BPH
Approval in Country
General Indication
Prostate diseases, ablation of prostate tissue etc.

For full list of indications click here

Sonablate® has received approval in over 50 countries worldwide. In the United States, Sonablate is indicated for the ablation of prostate tissue. For specific indications per country, visit www.sonablate.com/indications.
‍
As with any medical procedure, individual results may vary. Most common side effects include pain and discomfort and urinary tract infection (UTI). Rare side effects include rectal injury, which may require intervention. Consult the Instructions for Use (IFU) for more information.
‍
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
‍
Sonablate is a registered trademark of Sonablate Corp.
‍
© 2023 Sonablate Corp. All rights reserved.

Sonablate White Logo With HIFU
Contact Us
10130 Perimeter Pkwy, Suite 410 Charlotte, NC 28216
888-874-4384
info@sonablate.com
Connect With Us
Quick Links
Sonablate HIFU
About Us
Terms and Conditions
Accessibility
Privacy

Sonablate® HIFU is approved in more than 50 countries worldwide and was the first focused ultrasound device to be FDA-cleared in the U.S. for the ablation of prostate tissue. This innovative solution for prostate diseases has allowed Sonablate® HIFU to become the industry leader in focal therapy. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
‍
Sonablate is a registered trademark of Sonablate Corp. © 2023 Sonablate Corp. All rights reserved.